GeneFerm Biotechnology Co Ltd (1796) — Free Cash Flow Generation Index
GeneFerm Biotechnology Co Ltd (1796) has a Free Cash Flow Generation Index of -3.13x as of June 2025. Free cash flow of NT$-4.53 Million represents -3% of operating cash flow (NT$1.45 Million). See 1796 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
GeneFerm Biotechnology Co Ltd Free Cash Flow Generation Index (2017–2024)
Historical FCF Generation Index trend for GeneFerm Biotechnology Co Ltd across 8 annual periods. Explore cash flow to debt ratio of GeneFerm Biotechnology Co Ltd to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year Free Cash Flow Generation Index for GeneFerm Biotechnology Co Ltd. For the full company profile including market capitalisation, see GeneFerm Biotechnology Co Ltd (1796) market capitalisation.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.81x | NT$-14.61 Million | NT$8.09 Million | NT$22.70 Million | ▼ -389.0% |
| 2023 | 0.62x | NT$118.91 Million | NT$190.31 Million | NT$71.40 Million | ▲ +149.0% |
| 2022 | -1.27x | NT$-155.98 Million | NT$122.43 Million | NT$278.42 Million | ▼ -328.4% |
| 2021 | -0.30x | NT$-33.37 Million | NT$112.23 Million | NT$145.61 Million | ▲ +35.2% |
| 2020 | -0.46x | NT$-25.90 Million | NT$56.42 Million | NT$82.32 Million | ▲ +83.1% |
| 2019 | -2.72x | NT$-39.89 Million | NT$14.69 Million | NT$54.57 Million | ▼ -995.1% |
| 2018 | 0.30x | NT$12.78 Million | NT$42.14 Million | NT$28.81 Million | ▲ +269.2% |
| 2017 | 0.08x | NT$5.02 Million | NT$61.08 Million | NT$55.16 Million | — |